GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Cyclically Adjusted PB Ratio

BriaCell Therapeutics (TSX:BCT) Cyclically Adjusted PB Ratio : 0.46 (As of Dec. 13, 2024)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-12-13), BriaCell Therapeutics's current share price is C$0.95. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jul. 2024 was C$2.06. BriaCell Therapeutics's Cyclically Adjusted PB Ratio for today is 0.46.

The historical rank and industry rank for BriaCell Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSX:BCT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.97
Current: 0.77

During the past years, BriaCell Therapeutics's highest Cyclically Adjusted PB Ratio was 0.97. The lowest was 0.00. And the median was 0.00.

TSX:BCT's Cyclically Adjusted PB Ratio is ranked better than
65.44% of 599 companies
in the Biotechnology industry
Industry Median: 1.58 vs TSX:BCT: 0.77

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share data for the three months ended in Jul. 2024 was C$-0.179. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$2.06 for the trailing ten years ended in Jul. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted PB Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.12 0.23 0.52 0.50

BriaCell Therapeutics Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.50 0.83 1.45 0.50

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.



BriaCell Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.95/2.06
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jul. 2024 is calculated as:

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Jul. 2024 was:

Adj_Book=Book Value per Share/CPI of Jul. 2024 (Change)*Current CPI (Jul. 2024)
=-0.179/128.0748*128.0748
=-0.179

Current CPI (Jul. 2024) = 128.0748.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201410 11.591 99.473 14.924
201501 7.126 98.209 9.293
201504 6.752 99.710 8.673
201507 5.279 100.579 6.722
201510 4.040 100.500 5.148
201601 2.627 100.184 3.358
201604 4.785 101.370 6.046
201607 3.375 101.844 4.244
201610 6.411 102.002 8.050
201701 5.383 102.318 6.738
201704 6.005 103.029 7.465
201707 2.697 103.029 3.353
201710 3.319 103.424 4.110
201801 1.558 104.056 1.918
201804 5.686 105.320 6.914
201807 2.343 106.110 2.828
201810 0.876 105.952 1.059
201901 -1.475 105.557 -1.790
201904 1.314 107.453 1.566
201907 -1.380 108.243 -1.633
201910 -1.490 107.927 -1.768
202001 -4.101 108.085 -4.859
202004 -5.363 107.216 -6.406
202007 -6.725 108.401 -7.945
202010 -5.768 108.638 -6.800
202101 -5.985 109.192 -7.020
202104 2.291 110.851 2.647
202107 2.271 112.431 2.587
202110 4.481 113.695 5.048
202201 3.776 114.801 4.213
202204 3.728 118.357 4.034
202207 0.861 120.964 0.912
202210 0.912 121.517 0.961
202301 -0.111 121.596 -0.117
202304 -0.512 123.571 -0.531
202307 -0.312 124.914 -0.320
202310 0.233 125.310 0.238
202401 -0.678 125.072 -0.694
202404 -0.510 126.890 -0.515
202407 -0.179 128.075 -0.179

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics  (TSX:BCT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BriaCell Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Jamieson Bondarenko Director
Marc Lustig 10% Security Holder, Director
Gadi Levin Senior Officer
William Williams Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines